Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01296581Phase 1Completed

Safety Study of X-82 in Patients With Advanced Solid Tumors

Role: lead

NCT02348359Phase 2Terminated

X-82 to Treat Age-related Macular Degeneration

Role: lead

NCT01784861Phase 1Terminated

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Role: collaborator

NCT02146222Phase 1Completed

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors

Role: collaborator

NCT01674569Phase 1Completed

Pilot Study of X-82 in Patients With Wet AMD

Role: lead

All 5 trials loaded